Baseline Dopamine Dependent Drug Effects of Methylphenidate and Sulpiride on Brain and Behaviour: A PET, Pharmaco-fMRI Study

Completed

• Conditions: distractability; lack of motivation; 10009841

• Registration Number: NL-OMON43196
• Lead Sponsor: Radboud Universiteit Nijmegen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-06-20
• Results First Posted: 2020-09-12
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Healthy volunteers between 18 and 45 years of age

Exclusion Criteria

Neuropsychiatric disorders; history of drug abuse; heart problems; metal objects in or around the body (see section 4.3 in research protocol (C1) for full list of exclusion criteria)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Baseline dopamine synthesis capacity measured with [18F]-DOPA PET; BOLD signal<br /><br>measured with fMRI; behavioural performance on computerized tasks (measuring<br /><br>reward sensitivity, working memory, reversal learning, reinforcement learning,<br /><br>cognitive effort, the influence of affective information on goal-oriented<br /><br>behaviour, and creativity); subjective measurements (e.g. self-report<br /><br>questionnaires, visual analogue scales); psychophysiological recordings (e.g.,<br /><br>blood pressure, heart rate, respiration, elctrocardiography); blood and saliva<br /><br>sample to assess dopamine genes for pathway-based genetics analysis.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>All tasks in the cognitive testing battery (computerized tasks) result in both<br /><br>outcomes of primary interest (see section 7.1.1 in the study protocol) and<br /><br>additional outcomes (see section 7.1.2 in the study protocol). Our secondary<br /><br>objective is to further our understanding of the relationship between baseline<br /><br>dopamine synthesis capacity and baseline measures - such as working memory,<br /><br>genetic differences, impulsivity and eye-blink rate * to assess how baseline<br /><br>levels of dopamine mediate the effects of the drug on the secondary outcomes<br /><br>from the cognitive testing battery.</p><br>